Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Other Current Assets

Current assets not reported separately, such as prepaid expenses.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Other Current Assets · Q2 FY2026 · quarter ended Jun 2026

Other current assets of $3.27M in Q2 FY2026

Q2 FY2026 other current assets was $3.27M.

Context

  • Other current assets amounted to 2.5% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.27M-18.7% QoQ
Last fiscal yearDec 2025
$4.03M+27.5% YoY
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+27.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
4.03M USD
Year-over-year change
+27.5%
1-year CAGR
+27.5%

Other Current Assets vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
  • Other current assets amounts to 2.5% of total assets for ATTO, versus a peer median of 1.3%.
ATTO Competitors
Other Current Assets for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$32.96M USD——8.2%
ALMSAlumis Inc. Common StockJun 2026$7.93M USD-66.1%+233.6%1.4%
QTTBQ32 Bio Inc.Mar 2026$6.45M USD+6836.6%+259.0%10.1%
EVMNEvommune, Inc.Mar 2026$4.39M USD-25.7%—1.4%
ANABAnaptysBio, Inc.Mar 2026$3.91M USD-26.2%+1.6%1.2%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€3.43M EUR——2.1%
ATTOAttovia Therapeutics, Inc.Jun 2026$3.27M USD——2.5%
ZURAZura Bio LimitedMar 2026$1.41M USD+25.6%+148.4%0.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$29K USD-93.1%—0.1%
ORKAOruka Therapeutics, Inc.Sep 2026$0 USD-100.0%+199.3%0.0%
ACRSAclaris Therapeutics, Inc.Mar 2026$0 USD-100.0%+59.8%0.0%
Peer median (excluding ATTO) —-46.1%+173.9%1.3%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.